Clinical Trials
2 trialsNCT06480552 2026-06-04
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Recruiting
NCT05067283 2026-05-26
KANDLELIT-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting